1346819-04-2Relevant articles and documents
Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}- N-methylpyridine-2-carboxamide (AZD5305): A PARP1-DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs
Balazs, Amber,Barratt, Derek,Bista, Michal,Chuba, Matthew D.,Cosulich, Sabina,Critchlow, Susan E.,Degorce, Sébastien L.,Di Fruscia, Paolo,Edmondson, Scott D.,Embrey, Kevin,Fawell, Stephen,Ghosh, Avipsa,Gill, Sonja J.,Gunnarsson, Anders,Hande, Sudhir M.,Heightman, Tom D.,Hemsley, Paul,Illuzzi, Giuditta,Johannes, Jeffrey W.,Lane, Jordan,Larner, Carrie,Leo, Elisabetta,Liu, Lina,Madin, Andrew,Martin, Scott,McWilliams, Lisa,O'Connor, Mark J.,Orme, Jonathan P.,Pachl, Fiona,Packer, Martin J.,Pei, Xiaohui,Pike, Andrew,Schimpl, Marianne,She, Hongyao,Staniszewska, Anna D.,Talbot, Verity,Underwood, Elizabeth,Varnes, Jeffrey G.,Xue, Lin,Yao, Tieguang,Zhang, Andrew X.,Zhang, Ke,Zheng, Xiaolan
supporting information, p. 14498 - 14512 (2021/10/20)
Poly-ADP-ribose-polymerase (PARP) inhibitors have achieved regulatory approval in oncology for homologous recombination repair deficient tumors including BRCA mutation. However, some have failed in combination with first-line chemotherapies, usually due to overlapping hematological toxicities. Currently approved PARP inhibitors lack selectivity for PARP1 over PARP2 and some other 16 PARP family members, and we hypothesized that this could contribute to toxicity. Recent literature has demonstrated that PARP1 inhibition and PARP1-DNA trapping are key for driving efficacy in a BRCA mutant background. Herein, we describe the structure- and property-based design of 25 (AZD5305), a potent and selective PARP1 inhibitor and PARP1-DNA trapper with excellent in vivo efficacy in a BRCA mutant HBCx-17 PDX model. Compound 25 is highly selective for PARP1 over other PARP family members, with good secondary pharmacology and physicochemical properties and excellent pharmacokinetics in preclinical species, with reduced effects on human bone marrow progenitor cells in vitro.
Metabolites in safety testing assessment in early clinical development: A case study with a glucokinase activator
Sharma, Raman,Litchfield, John,Atkinson, Karen,Eng, Heather,Amin, Neeta B.,Denney, William S.,Pettersen, John C.,Goosen, Theunis C.,Di, Li,Lee, Esther,Pfefferkorn, Jeffrey A.,Dalvie, Deepak K.,Kalgutkar, Amit S.
supporting information, p. 1926 - 1939 (2016/10/12)
The present article summarizes Metabolites in Safety Testing (MIST) studies on a glucokinase activator, N,N-dimethyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide (PF-04937319), which is under development for the treatment of type 2 diametes mellitus. Metabolic profiling in rat, dog, and human hepatocytes revealed that PF-04937319 is metabolized via oxidative (major) and hydrolytic pathways (minor). N-Demethylation to metabolite M1 [N-methyl-5-((2-methyl-6-((5-methylpyrazin-2-yl)carbamoyl)benzofuran-4-yl)oxy)pyrimidine-2-carboxamide] was the major metabolic fate of PF-04937319 in human (but not rat or dog) hepatocytes, and was catalyzed by CYP3A and CYP2C isoforms. Qualitative examination of circulating metabolites in humans at the 100- and 300-mg doses from a 14-day multiple dose study revealed unchanged parent drug and M1 as principal components. Because M1 accounted for 65% of the drug-related material at steady state, an authentic standard was synthesized and used for comparison of steady-state exposures in humans and the 3-month safety studies in rats and dogs at the no-observed-adverse-effect level. Although circulating levels of M1 were very low in beagle dogs and female rats, adequate coverage was obtained in terms of total maximal plasma concentration (～7.7x and 1.8x) and area under the plasma concentration-time curve (AUC; 3.6x and 0.8x AUC) relative to the 100- and 300-mg doses, respectively, in male rats. Examination of primary pharmacology revealed M1 was less potent as a glucokinase activator than the parent drug (compound PF-04937319: EC50 = 0.17 μM; M1: EC50 = 4.69 μM). Furthermore, M1 did not inhibit major human P450 enzymes (IC50 > 30 μM), and was negative in the Salmonella Ames assay, with minimal offtarget pharmacology, based on CEREP broad ligand profiling. Insights gained from this analysis should lead to a more efficient and focused development plan for fulfilling MIST requirements with PF-04937319.
BRADYKININ RECEPTOR AGONISTS AND USES THEREOF TO TREAT OCULAR HYPERTENSION AND GLAUCOMA
-
Page/Page column 35, (2012/03/10)
The invention provides compositions and methods for treating and/or preventing ocular disorders associated with increased intraocular pressure. In particular, the compounds are bradykinin agonists.
HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISEASES
-
Page/Page column 101, (2011/11/30)
The invention relates to compounds of Formula (1) and to processes for the preparation of, intermediates used in the preparation of, compositions containing and the uses of, such derivatives. The compounds according to the present invention are useful in numerous diseases in which ALK protein is involved or in which inhibition of ALK activity may induce benefit, especially for the treatment of cancer mediated by a mutated EML4-ALK fusion protein.
